• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Hopeful Signs for These 2 Small Biotech Stocks

Few parts of this biotech space are more frustrating that what I have dubbed 'Tier 3' biotech concerns.
By BRET JENSEN
May 10, 2019 | 09:14 AM EDT
Stocks quotes in this article: XBI, SRPT, FLXN, DVAX

Being an investor in the small biotech space requires the patience of Job at times. The sector consistently goes through bouts of euphoria always followed by longer periods of negativity. Just look at the chart of the SPDR S&P Biotech ETF (XBI) over the past five years.

Despite most of the market indices being at all-time highs until this week's pull back, the small biotech sector is slightly below where it was during its last peak of July of 2015. That is almost four years. Of course, the sector had quadrupled over a few years leading into that last peak.

Few parts of the small biotech space are more frustrating that what I have dubbed 'Tier 3' biotech concerns. These are companies that have recently got FDA approval for the primary products in their pipeline but are some ways to profitability. A non-biotech investor would think FDA approval is the biggest hurdle for most small biotech companies and would be rewarded by the market.

Unfortunately, that is not the case. This is why so many small biotech stocks frequently decline in the quarters following the initial euphoria of FDA approval. Developing a drug and getting it through the approval process is a daunting and complex endeavor. Making it successful commercially can be just as challenging. There are sale forces to be built, doctors and consumers to educate, and government as well as private insurance networks to get the necessary approval from for coverage.

This is why initial drug rollouts are usually slower and consume more cash that investors expect after the FDA green light is granted. This is a primary reason so many of these stocks have significant pullbacks soon after FDA approval. This is also why I sell covered calls against most of my small biotech stocks leading into an FDA decision. It is a good risk mitigation device. While there are some exceptions like Sarepta Therapeutics (SRPT) where money is left on the table, this is usually the right way to go.

Fortunately, two stocks that have gone through this journey and have lost significant value since their FDA approvals showed some good commercialization progress during their first quarters. These Q1 results resulted in both names rallying over 15% in trading yesterday.

Let's start with Flexion Therapeutics (FLXN) that posted revenue from its recently approved product Zilretta of $10.6 million. This was inline with estimates and up from $9.5 million of sales in the fourth quarter and an almost 400% increase from the year ago period. More importantly, initial sales for April came in at $5.1 million showing an acceleration of sales growth. The company confirmed full year revenue guidance of $65 million to $80 million. April sales numbers gave those estimates credence.

Dynavax Technologies (DVAX)  also reported revenues in line with estimates. Sales of its recently approved hepatitis B vaccine 'Heplisav-B' came in at $5.6 million, 44% above the previous quarter. The company made good progress in the quarter getting the vaccine into the hands of its key accounts and reorder activity was strong as well. Dynavax has some posters for another developing pipeline asset at the big ASCO conference in a few weeks. I could also see a partnership deal for its oncology compound 'SD-101' as some point during 2019.

Both stocks had big relief rallies on these solid results. While too early to tell for sure, Q1 reports could end up being significant inflection points for the companies and their shareholders.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Bret Jensen was Long DVAX, FLXN, XBI.

TAGS: Drug Approvals | Investing | Markets | Stocks | Trading | Biotechnology

More from Investing

This Is No Market for Complacent Traders

Helene Meisler
Jan 25, 2021 6:00 AM EST

Let's look at signs of excess in the market and how they compare with past action.

Bearish Bets: 2 NYSE Stocks You Should Consider Shorting This Week

Bob Lang
Jan 24, 2021 10:30 AM EST

These names are displaying both quantitative and technical deterioration.

Price Targets: How They Mislead and How They Can be Used

James "Rev Shark" DePorre
Jan 23, 2021 10:00 AM EST

The main problem with price targets is that they are a static number in a dynamic situation.

Stock Market Continues to Defy Conventional Wisdom

James "Rev Shark" DePorre
Jan 22, 2021 5:04 PM EST

Concerns about the action being overheated remain, but rotational action keeps the momentum going.

AMC Is a High Risk, High Reward Play

Timothy Collins
Jan 22, 2021 2:15 PM EST

Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login